Healthlead PCL (BKK:HL) Beneish M-Score: -2.76 (As of Jun. 27, 2026)


BKK:HL Healthlead PCL BKK:HL
76 GF Score
Price ฿5.50
GF Value ฿10.82
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Healthlead PCL Beneish M-Score?

Healthlead PCL BKK:HL -1.79% 76 Beneish M-Score is -2.76 as of Jun. 27, 2026. GuruFocus rates BKK:HL with a GF Score™ of 76/100 and a GF Value™ of ฿10.82 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 633 Healthcare Providers & Services companies, Healthlead PCL ranks better than 65.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.76 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Healthlead PCL's Beneish M-Score or its related term are showing as below:

BKK:HL' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.38   Max: -1.95
Current: -2.76

During the past 7 years, the highest Beneish M-Score of Healthlead PCL was -1.95. The lowest was -2.90. And the median was -2.38.


Healthlead PCL Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Healthlead PCL's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healthlead PCL Beneish M-Score Chart

Healthlead PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.38 -2.01 -2.41 -2.90

Healthlead PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -2.47 -2.29 -2.90 -2.76

Healthlead PCL Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, Healthlead PCL's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healthlead PCL Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Healthlead PCL's Beneish M-Score falls into.


BKK:HL
76GF Score
Healthlead PCL BKK:HL
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healthlead PCL Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Healthlead PCL for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1653+0.528 * 0.9731+0.404 * 0.7455+0.892 * 1.087+0.115 * 0.8714
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0461+4.679 * -0.067277-0.327 * 1.1587
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ฿39 Mil.
Revenue was 585.133 + 565.119 + 545.636 + 548.297 = ฿2,244 Mil.
Gross Profit was 138.98 + 148.689 + 128.279 + 133.51 = ฿549 Mil.
Total Current Assets was ฿945 Mil.
Total Assets was ฿1,563 Mil.
Property, Plant and Equipment(Net PPE) was ฿545 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿95 Mil.
Selling, General, & Admin. Expense(SGA) was ฿490 Mil.
Total Current Liabilities was ฿312 Mil.
Long-Term Debt & Capital Lease Obligation was ฿275 Mil.
Net Income was 18.541 + 27.831 + 12.767 + 16.804 = ฿76 Mil.
Non Operating Income was 0.077 + -0.024 + -0.267 + 0.015 = ฿-0 Mil.
Cash Flow from Operations was 35.041 + 68.057 + 41.596 + 36.576 = ฿181 Mil.
Total Receivables was ฿31 Mil.
Revenue was 569.8 + 526.531 + 503.202 + 464.941 = ฿2,064 Mil.
Gross Profit was 131.947 + 135.117 + 117.118 + 107.679 = ฿492 Mil.
Total Current Assets was ฿908 Mil.
Total Assets was ฿1,552 Mil.
Property, Plant and Equipment(Net PPE) was ฿547 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿82 Mil.
Selling, General, & Admin. Expense(SGA) was ฿431 Mil.
Total Current Liabilities was ฿242 Mil.
Long-Term Debt & Capital Lease Obligation was ฿261 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(38.692 / 2244.185) / (30.543 / 2064.474)
=0.017241 / 0.014795
=1.1653

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(491.861 / 2064.474) / (549.458 / 2244.185)
=0.23825 / 0.244836
=0.9731

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (945.261 + 544.606) / 1562.618) / (1 - (907.726 + 547.144) / 1551.781)
=0.046557 / 0.062451
=0.7455

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2244.185 / 2064.474
=1.087

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(81.687 / (81.687 + 547.144)) / (95.411 / (95.411 + 544.606))
=0.129903 / 0.149076
=0.8714

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(489.734 / 2244.185) / (430.662 / 2064.474)
=0.218224 / 0.208606
=1.0461

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((274.919 + 311.514) / 1562.618) / ((261.028 + 241.558) / 1551.781)
=0.375289 / 0.323877
=1.1587

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(75.943 - -0.199 - 181.27) / 1562.618
=-0.067277

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Healthlead PCL has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.76 mean?
Healthlead PCL (BKK:HL) has a Beneish M-Score of -2.76 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Healthlead PCL and its competitors. According to the industry distribution chart, Healthlead PCL ranks #221 out of 633 companies in the Healthcare Providers & Services industry, placing it in the top 34.9%.
Is Healthlead PCL's Beneish M-Score too high?
Healthlead PCL's current Beneish M-Score is -2.76. Based on the distribution chart, Healthlead PCL ranks #221 out of 633 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #221 out of 633 companies for Beneish M-Score. This puts Healthlead PCL in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Healthlead PCL and its competitors. Healthlead PCL's current Beneish M-Score is -2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.82, compared to a current price of ฿5.50 — trading 49.2% below its estimated fair value. The current Beneish M-Score is -2.76. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current Beneish M-Score is -2.76 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healthlead PCL (BKK:HL) Overvalued in 2026?

Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued. The current stock price of ฿5.50 is trading 49.2% below its estimated GF Value™ of ฿10.82. GuruFocus considers Healthlead PCL to be Significantly Undervalued.

Key valuation signals for BKK:HL:

  • Beneish M-Score: -2.76
  • GF Value™: ฿10.82 vs. price of ฿5.50 (49.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healthlead PCL Business Description

Address 99/4 Moo 10, Bang Muang Sub-District, Bang-Yai District, Nonthaburi, THA, 11140
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score

Get the complete analysis for BKK:HL

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿5.50
Price
฿10.82
GF Value